✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Gusperimus is an investigational drug.
There have been 4 clinical trials for Gusperimus. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2011.
The most common disease conditions in clinical trials are Granulomatosis with Polyangiitis, Lupus Nephritis, and Nephritis. The leading clinical trial sponsors are Nippon Kayaku Co., Ltd., Nippon Kayaku Co.,Ltd., and Nordic Pharma SAS.
Recent Clinical Trials for Gusperimus
|Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis||Nordic Pharma SAS||Phase 3|
|Efficacy and Safety of Deoxyspergualin in Renal Transplant Patient With Chronic Rejection||Nippon Kayaku Co., Ltd.||N/A|
|Efficacy and Safety of Deoxyspergualin in Renal Transplant Patient With Chronic Rejection||Nippon Kayaku Co.,Ltd.||N/A|